Study of Ixazomib With Pegylated IFN-alpha 2b (pIFN) in Metastatic Renal Cell Carcinoma (mRCC)

NCT02447887 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

3

Enrollment

OTHER

Sponsor class

Stopped IRB study closure facilitated by Investigator

Conditions

Metastatic Renal Cell Carcinoma
RCC

Interventions

DRUG: Ixazomib
DRUG: Pegylated IFN-alpha 2b

Sponsor

Fox Chase Cancer Center